| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
CERTAIN INFORMATION CONTAINED IN THIS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PR... |
| 02 Oct 2026 |
8-K: Other Events
On October 1, 2026, OPKO Health, Inc. (the “Company”) determined that its 3.75% Convertible Senior Notes due 2029 (the “Notes”), of which approximately $121 million is outstanding, are convertible by holders of such Notes through Decembe... |
| 14 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amended Agreeme... |
| 27 Jul 2026 |
8-K: Results of Operations and Financial Condition
MIAMI, July 27, 2026 – OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlight... |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, OPKO Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting and the ... |
| 28 Apr 2026 |
8-K: Results of Operations and Financial Condition
MIAMI, April 28, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. |
| 19 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 18, 2026, the Board of Directors of OPKO Health, Inc. (the “Company”), appointed Subbarao V. Uppaluri, Ph.D. as a new director with immediate effect to serve until the Company’s 2026 Annual Meeting of Stockholders and until his ... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
MIAMI, February 26, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full yea... |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition
MIAMI, October 29, 2025 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. |
| 15 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
MIAMI, July 31, 2025 – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. |
| 29 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 27, 2025, the Compensation Committee of the Board of Directors (the “Committee”) of OPKO Health, Inc. (the “Company”) held a meeting to review certain compensation matters for the Company’s executive officers and non-executive emp... |
| 30 Apr 2025 |
8-K: Results of Operations and Financial Condition
MIAMI (April 30, 2025) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. |
| 23 Apr 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On April 23, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting and the corresponding votes. |
| 01 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
As previously reported, on March 27, 2025, OPKO Health, Inc., a Delaware corporation (the “Company”), entered into exchange agreements (the “Exchange Agreements” and each an “Exchange Agreement”) with certain institutional holders (the “... |
| 28 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On March 27, 2025, OPKO Health, Inc., a Delaware corporation (the “Company”), entered into exchange agreements (the “Exchange Agreements” and each an “Exchange Agreement”) with certain institutional holders (the “Noteholders”) of the Com... |
| 11 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Shared Customer Accounts (Schedule to be delivered by Buyer at Closing and may be updated from time to time thereafter in accordance with Section 1.5(b)(i)(F)) |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
MIAMI (February 27, 2025) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. |
| 15 Jan 2025 |
8-K: Regulation FD Disclosure
On January 15, 2025, members of management for OPKO Health, Inc. (the “Company”) attended and will participate in meetings with investors at the 43rd Annual J.P. Morgan Healthcare Conference. A copy of the Company’s presentation material... |
Loading...